Miracle Mile Advisors LLC lessened its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 82.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,042 shares of the company's stock after selling 32,978 shares during the period. Miracle Mile Advisors LLC's holdings in AstraZeneca were worth $474,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Fairfield Bush & CO. purchased a new position in AstraZeneca in the 2nd quarter worth approximately $25,000. ICA Group Wealth Management LLC purchased a new position in AstraZeneca in the 4th quarter worth approximately $26,000. Anchor Investment Management LLC purchased a new stake in shares of AstraZeneca in the 4th quarter valued at $26,000. Parkside Financial Bank & Trust boosted its stake in shares of AstraZeneca by 4,875.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company's stock valued at $26,000 after purchasing an additional 390 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA purchased a new stake in shares of AstraZeneca in the 4th quarter valued at $27,000. Hedge funds and other institutional investors own 20.35% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on AZN shares. Morgan Stanley started coverage on shares of AstraZeneca in a research note on Tuesday, January 23rd. They issued an "overweight" rating for the company. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a "hold" rating to a "sell" rating in a research note on Thursday, February 8th. HSBC started coverage on shares of AstraZeneca in a research report on Monday, December 18th. They set a "buy" rating for the company. Finally, Jefferies Financial Group cut shares of AstraZeneca from a "buy" rating to a "hold" rating in a research report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $80.00.
View Our Latest Stock Report on AstraZeneca
AstraZeneca Trading Down 0.3 %
AZN traded down $0.19 during trading on Wednesday, hitting $66.81. 3,795,681 shares of the stock traded hands, compared to its average volume of 6,214,817. The firm has a market capitalization of $207.14 billion, a P/E ratio of 34.80, a price-to-earnings-growth ratio of 1.24 and a beta of 0.50. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.82 and a quick ratio of 0.64. The firm has a 50-day moving average of $65.69 and a 200 day moving average of $65.80. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $76.56.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The company had revenue of $12.02 billion during the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter last year, the company posted $0.69 earnings per share. The firm's revenue for the quarter was up 7.3% compared to the same quarter last year. Equities research analysts anticipate that AstraZeneca PLC will post 4.01 EPS for the current year.
AstraZeneca Increases Dividend
The firm also recently declared a Semi-Annual dividend, which was paid on Monday, March 25th. Investors of record on Friday, February 23rd were paid a $0.965 dividend. This represents a dividend yield of 2.3%. This is a positive change from AstraZeneca's previous Semi-Annual dividend of $0.47. The ex-dividend date was Thursday, February 22nd. AstraZeneca's dividend payout ratio (DPR) is presently 100.52%.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
